Latest & greatest articles for travoprost

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on travoprost or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on travoprost and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for travoprost

1. Travoprost

Travoprost Top results for travoprost - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for travoprost The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

2. travoprost ophthalmic solution (Izba)

travoprost ophthalmic solution (Izba) travoprost ophthalmic solution | CADTH.ca Find the information you need travoprost ophthalmic solution travoprost ophthalmic solution Last Updated: January 31, 2017 Result type: Reports Project Number: SR0516-000 Product Line: Generic Name: travoprost ophthalmic solution Brand Name: Izba Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: open-angle glaucoma Submission Type: New Project Status: Active Files Follow us: © 2017 Canadian Agency

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2017

3. TRAVATAN (travoprost), glaucoma eye drops

TRAVATAN (travoprost), glaucoma eye drops Haute Autorité de Santé - TRAVATAN (travoprost), collyre anti-glaucomateux Contribuer à la régulation par la qualité et l'efficience Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments TRAVATAN (travoprost), collyre anti-glaucomateux Substance active (DCI) travoprost OPHTALMOLOGIE - Nouvelle indication Nature de la demande Extension d'indication Avis de la CT du 05 octobre (...) démonstration de non infériorité du travoprost par rapport au timolol après 12 semaines de traitement sur la réduction de la pression intraoculaire chez l’enfant, la Commission considère que TRAVATAN (travoprost) n’apporte pas d’amélioration du service médical rendu (ASMR V) dans la stratégie thérapeutique de prise en charge des patients pédiatriques ayant une pression intraoculaire élevée et souffrant de glaucome pédiatrique qui comprend la chirurgie et les collyres anti glaucomateux (latanoprost, timolol

Haute Autorite de sante2016

4. Travoprost (Travatan) - for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma

Travoprost (Travatan) - for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma %PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x���n�F�݀���b�s'�t�mwӦ�}H�@K�-�%�$��߸眙�H�#��`��3g��Ɖ�?Goޜz�������}�>���D�Yb"�2�K��s���e�|uzr�ê�-u�}�rz������m

All Wales Medicines Strategy Group2015

5. Travoprost (Travatan®)

Travoprost (Travatan®) Travoprost (Travatan®) Travoprost (Travatan®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Travoprost (Travatan®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG (...) Secretariat Assessment Report Advice No. 2601. 2015 Authors' conclusions Travoprost (Travatan®) is recommended as an option for use within NHS Wales for the decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Cloprostenol; Glaucoma; Humans; Intraocular Pressure; Ocular Hypertension; Prostaglandins F, Synthetic; Wales Language Published

Health Technology Assessment (HTA) Database.2015

6. Travoprost (Travatan) - decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma

Travoprost (Travatan) - decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma Published 12 October 2015 Product Update: Travoprost 40 micrograms/mL eye drops (Travatan®) SMC No. (1091/15) Alcon Eye Care UK Ltd 4 September 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland (...) . The advice is summarised as follows: ADVICE: following an abbreviated submission travoprost (Travatan ® ) is accepted for use within NHS Scotland. Indication under review: decrease of elevated intraocular pressure in paediatric patients aged 2 months to <18 years with ocular hypertension or paediatric glaucoma. In a randomised, double-masked study of paediatric patients with glaucoma or ocular hypertension, travoprost was demonstrated to be non-inferior to a beta blocker eye drop preparation in terms

Scottish Medicines Consortium2015

8. Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database

Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Treatment (...) persistence and cost-effectiveness of latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprost-timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database Lafuma A, Salmon JF, Robert J, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical

NHS Economic Evaluation Database.2011

9. Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: a systematic review and meta-analysis

Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: a systematic review and meta-analysis Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: a systematic review and meta-analysis Effects of travoprost in the treatment of open-angle glaucoma or ocular hypertension: a systematic review and meta-analysis Cheng JW, Xi GL, Wei RL, Cai JP, Li Y CRD summary This review found that travoprost was as effective as latanoprost in lowering (...) intraocular pressure in patients with open-angle glaucoma or ocular hypertension; both interventions were generally well-tolerated. This was a generally well-conducted review and the authors' conclusions are likely to be reliable. Authors' objectives To compare the efficacy and tolerability of travoprost and latanoprost in the treatment of open-angle glaucoma or ocular hypertension. Searching MEDLINE, EMBASE, the Cochrane Library and the Chinese Biomedical database were searched without language

DARE.2009

10. Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database

Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients (...) with ocular hypertension or glaucoma: analysis based on the UK General Practitioner Research Database De Natale R, Lafuma A, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of travoprost

NHS Economic Evaluation Database.2009

11. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France

Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France Payet S, Denis P, Berdeaux G, Launois R Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to assess the costs and effects of travoprost and latanoprost as single treatments for glaucoma in France. The authors concluded that travoprost was very cost-effective, producing fewer treatment changes, at a small increase in cost, which was acceptable

NHS Economic Evaluation Database.2008

12. Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database

Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination in first-line treatment of glaucoma: analysis conducted on the United Kingdom General Practitioner Research Database Costs and effectiveness of travoprost versus a dorzolamide + timolol fixed combination (...) and effectiveness of travoprost versus dorzolamide and timolol. The authors concluded that travoprost dominated dorzolamide and timolol, as it was both more effective and less costly. Although the authors used a retrospective design, the methodology was good and appropriate statistical methods were used to control for biases. The methods and results were well reported and the conclusions appear to be appropriate. Type of economic evaluation Cost-effectiveness analysis Study objective The objective

NHS Economic Evaluation Database.2007

13. Travoprost and timolol maleate

Travoprost and timolol maleate Common Drug Review CEDAC Meeting – July 26, 2006 Page 1 of 1 Notice of CEDAC Final Recommendation – August 24, 2006 CEDAC FINAL RECOMMENDATION and REASONS for RECOMMENDATION TRAVOPROST/TIMOLOL MALEATE (DuoTrav™ Ophthalmic Solution – Alcon Canada Inc.) Description: DuoTrav™ ophthalmic solution is a fixed dose combination of travoprost and timolol maleate that is approved for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma (...) or ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins, or other IOP lowering agents and when the use of the fixed combination drug is considered appropriate. Dosage Forms: Ophthalmic solution containing travoprost 0.004% and timolol 0.5% Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that DuoTrav™ ophthalmic solution be listed for use in patients who have not adequately responded to ophthalmic beta blocker drugs. Reasons

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2006

14. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials

Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis (...) of randomized controlled trials Li N, Chen X M, Zhou Y, Wei M L, Yao X CRD summary This review compared travoprost versus other prostaglandin analogues or timolol as treatments for open-angle glaucoma (OAG) or ocular hypertension (OH). Overall, travoprost 0.004% was more effective than timolol 0.5% for reducing intraocular pressure in patients with OAG or OH, and appears to be equivalent to other prostaglandin analogues. This was a well-conducted review and the authors' conclusions are likely to be reliable

DARE.2006

15. Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression

Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression Schmier J K, Halpern M T, Covert D W, Robin A L Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined two treatments for patients with primary open-angle glaucoma or ocular hypertension. Treatment was a fixed combination of latanoprost 0.005%/timolol 0.5% (L/T) or a fixed combination of travoprost 0.004%/timolol 0.5% (T/T). Type of intervention Treatment. Economic

NHS Economic Evaluation Database.2006

16. Travoprost/timolol (Duotrav)

Travoprost/timolol (Duotrav) Scottish Medicines Consortium Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6989 E-mail: Rosie.Murray@nhshealthquality.org Chairman Professor David Webb travoprost 0.004% / timolol 0.5% eye drops (Duotrav Ò ) (No. 294/06) Alcon Laboratories (UK) Ltd Product Update 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the above product and advises Area Drug and Therapeutic Committees (ADTCs) on its use in NHS (...) Scotland. The advice is summarised as follows: ADVICE: following an abbreviated submission Travoprost/timolol (Duotrav Ò ) eye drops are accepted for use in NHS Scotland for whom this is an appropriate combination of agents. They decrease intra-ocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues alone. There is no significant additional cost associated with the combination product compared

Scottish Medicines Consortium2006

17. Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom

Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Cost-effectiveness and cost-utility analysis (...) of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Netherlands and the United Kingdom Le Pen C, Ligier M, Berdeaux G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn

NHS Economic Evaluation Database.2005

18. Travoprost (Travatan)

Travoprost (Travatan) Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP Telephone 0141 225 6997 Fax 0141 248 3778 E-mail jmitchell@htbs.org.uk Chairman Professor David Lawson Scottish Medicines Consortium Travoprost (Travatan Ò ) No. 60/04 Alcon Laboratories Summary of Recommendation 9 February, 2004 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised (...) as follows: Advice: following a full submission Travoprost (Travatan ® ) is accepted for restricted use within NHS Scotland for the treatment of raised intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Use of travoprost, as monotherapy, should be restricted to patients who have contraindications to beta-blockers or have a history of adverse reactions to this group of drugs. It may also be indicated in addition to beta-blockers when required. It is one of a number

Scottish Medicines Consortium2004

19. Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects

Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Projected impact of travoprost versus both timolol and latanoprost on visual field deficit progression and costs among black glaucoma subjects Halpern M T, Covert D W, Robin A L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of travoprost 0.004% (Travatan) as an intraocular pressure (IOP)-lowering treatment for visual field deficit (VFD) progression among people with glaucoma. Individuals received one drop of travoprost in each eye

NHS Economic Evaluation Database.2002

20. Travatan (Travoprost) Ophthalmic Solution

Travatan (Travoprost) Ophthalmic Solution Drug Approval Package: Travatan (Travoprost) NDA #21-257 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Travatan (Travoprost) Ophthalmic Solution Company: Alcon Application No.: 21-257 Approval Date: 3/16/2001 (PDF) (PDF) Medical Review(s) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: August 20, 2001 Note: Documents in PDF format require the . - - Links

FDA - Drug Approval Package2001